Skip to content
10-K

Annual Report

Edwards Lifesciences Corp EW

0001099800-25-000005

← back to feed
Filed
Feb 28, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Jan 31, 2025 587.9M sh
Eps Diluted FY 2024 · Dec 31, 2024 $0.65
Eps Diluted FY 2024 · Sep 30, 2024 $5.13
Eps Diluted FY 2024 · Jun 30, 2024 $0.61
Eps Diluted FY 2024 · Mar 31, 2024 $0.58
Eps Diluted FY 2024 · Dec 31, 2023 $0.61
Eps Diluted FY 2024 · Sep 30, 2023 $0.63
Eps Diluted FY 2024 · Jun 30, 2023 $0.50
Eps Diluted FY 2024 · Mar 31, 2023 $0.56
Eps Diluted FY 2024 · Dec 31, 2022 $2.44
Eps Basic FY 2024 · Dec 31, 2024 $0.65
Eps Basic FY 2024 · Sep 30, 2024 $5.14
Eps Basic FY 2024 · Jun 30, 2024 $0.61
Eps Basic FY 2024 · Mar 31, 2024 $0.58
Eps Basic FY 2024 · Dec 31, 2023 $0.61
Eps Basic FY 2024 · Sep 30, 2023 $0.63
Eps Basic FY 2024 · Jun 30, 2023 $0.51
Eps Basic FY 2024 · Mar 31, 2023 $0.56
Eps Basic FY 2024 · Dec 31, 2022 $2.46
Net Income FY 2024 · Dec 31, 2024 $385.6M
Net Income FY 2024 · Sep 30, 2024 $3.07B
Net Income FY 2024 · Jun 30, 2024 $366.3M
Net Income FY 2024 · Mar 31, 2024 $351.9M
Net Income FY 2024 · Dec 31, 2023 $369.9M
Net Income FY 2024 · Sep 30, 2023 $384.9M
Net Income FY 2024 · Jun 30, 2023 $307.1M
Net Income FY 2024 · Mar 31, 2023 $340.5M
Net Income FY 2024 · Dec 31, 2022 $1.52B
Gross Profit FY 2024 · Dec 31, 2024 $1.09B
Gross Profit FY 2024 · Sep 30, 2024 $1.09B
Gross Profit FY 2024 · Jun 30, 2024 $1.09B
Gross Profit FY 2024 · Mar 31, 2024 $1.04B
Gross Profit FY 2024 · Dec 31, 2023 $1.02B
Gross Profit FY 2024 · Sep 30, 2023 $992.8M
Gross Profit FY 2024 · Jun 30, 2023 $1.03B
Gross Profit FY 2024 · Mar 31, 2023 $992.3M
Gross Profit restated FY 2024 · Dec 31, 2022 $3.74B
Revenue FY 2024 · Dec 31, 2024 $1.39B
Revenue FY 2024 · Sep 30, 2024 $1.35B
Revenue FY 2024 · Jun 30, 2024 $1.37B
Revenue FY 2024 · Mar 31, 2024 $1.33B
Revenue FY 2024 · Dec 31, 2023 $1.27B
Revenue FY 2024 · Sep 30, 2023 $1.24B
Revenue FY 2024 · Jun 30, 2023 $1.28B
Revenue FY 2024 · Mar 31, 2023 $1.22B
Revenue restated FY 2024 · Dec 31, 2022 $4.46B
Long Term Debt FY 2024 · Dec 31, 2023 $597M
Short Term Investments FY 2024 · Dec 31, 2023 $500.5M
Cash And Equivalents restated FY 2024 · Dec 31, 2023 $1.13B
Stockholders Equity FY 2024 · Dec 31, 2023 $6.65B
Current Liabilities FY 2024 · Dec 31, 2023 $1.2B
Total Liabilities FY 2024 · Dec 31, 2023 $2.64B
Current Assets FY 2024 · Dec 31, 2023 $4.04B
Total Assets FY 2024 · Dec 31, 2023 $9.36B
Shares Diluted FY 2024 · Dec 31, 2022 624.2M sh
Stock Repurchased FY 2024 · Dec 31, 2022 $1.73B
Capex FY 2024 · Dec 31, 2022 $244.6M
Operating Cash Flow FY 2024 · Dec 31, 2022 $1.22B
Sga Expense restated FY 2024 · Dec 31, 2022 $1.36B
Rd Expense restated FY 2024 · Dec 31, 2022 $843.6M
Operating Income restated FY 2024 · Dec 31, 2022 $1.5B
Cost Of Revenue restated FY 2024 · Dec 31, 2022 $723.7M